IP Library › Granted Patent US 10,689,361
Granted Patent B2
US 10,689,361 · App. 16/266,000 · Granted Jun 23, 2020

Quinoline derivative and use thereof

Inventor: Jianming Yin (Hangzhou, CN)
C07D401/12A61K31/47A61K31/4709A61P9/00A61P35/00C07D215/233C07D215/46C07D215/48
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,689,361
App. No.
16/266,000
Granted
Jun 23, 2020
Kind
B2
Abstract

Provided are a novel quinoline derivative, or a pharmaceutically acceptable salt, a hydrate, or a metabolite formed by metabolism in any form thereof, and use thereof in preparing a medicine for preventing and/or treating indications associated with angiogenesis. The quinoline derivative is an ideal and high-efficiency VEGFR inhibitor, and is able to be used to treat or prevent tumour growth and other metastasis growth diseases associated with angiogenesis.

Claims (13)

1. A quinoline derivative having a structure represented by Formula (I), a pharmaceutically acceptable salt, or a hydrate, thereof,

wherein:

R 1 is NHR 5 , wherein R 5 is five-membered unsaturated heterocycle containing 2 N, which is substituted by one methyl;

R 2 is selected from hydrogen, halogen, hydroxy, alkoxy and cyano;

R 3 and R 4 are independently selected from OR 6 , C(O)NH 2 and C(O)NHR 6 , wherein R 6 is C 1 -C 6 alkyl or halogenated alkyl;

X is selected from O;

non-exchangeable hydrogen is unsubstituted, or partially or fully substituted by deuterium in the quinoline derivative having the structure represented by Formula (I), or the pharmaceutically acceptable salt, or the hydrate thereof.

2. The quinoline derivative, the pharmaceutically acceptable salt, or the hydrate thereof according to claim 1 , wherein R 2 is Cl or F.

3. The quinoline derivative, the pharmaceutically acceptable salt, or the hydrate thereof according to claim 1 , wherein R 3 and R 4 are independently selected from OR 6 and C(O)NH 2 , the R 6 is methyl or ethyl.

4. The quinoline derivative, the pharmaceutically acceptable salt, or the hydrate, thereof according to claim 1 , wherein R 5 is

5. The quinoline derivative, the pharmaceutically acceptable salt, or the hydrate thereof according to claim 1 , wherein R 3 and R 4 are independently selected from C(O)NH 2 and C(O)NHR 6 , the R 6 is methyl or ethyl.

6. The quinoline derivative, the pharmaceutically acceptable salt, or the hydrate thereof according to claim 1 , wherein the quinoline derivative is the compound represented by the following structural formula,

7. A medicine for preventing and/or treating indications associated with angiogenesis, containing the quinoline derivative, the pharmaceutically acceptable salt, or the hydrate thereof according to claim 1 .

Priority Claims (1)
CN 2016 1 0649732 · Aug 9, 2016 · national
Continuity (2)
Continuation In Part PCTCN2017096569 · Aug 9, 2017
Related Publication 20190169163A1 · Jun 6, 2019